source
- OrbiMed raises two new life sciences funds worth $3B with one aiming for AsiaThe sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.BioSpace · 3d ago↗ source
- Merck and Moderna plan to seek approval for personalized mRNA melanoma vaccine after Phase 3 shows delayed recurrenceAt the 2026 STAT Summit, Merck and Moderna outlined their partnership to combine Keytruda with a personalized mRNA cancer vaccine aimed at melanoma patients. In a large Phase 3 trial, the vaccine…